Directs the Government Accountability Office (Comptroller General) to study the main regulatory barriers that block or slow new pharmaceutical manufacturing sites in the United States and that reduce U.S. competitiveness. The GAO must consider environmental and other regulations, technology options, and stakeholder views, and deliver findings and recommendations to Congress within one year of enactment.